Extensive-Stage Small Cell Lung Cancer research hub
15 indexed studies · 9 currently recruiting
- recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2 Randomized Trial of BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer
This study is testing a new medicine, BMS-986012, combined with standard treatments for a type of lung cancer called extensive-stage small cell lung cancer. Researchers want to see if the combination is safe and how well it works in people who haven't had treatment before.
Spain - recruitingTherapeutic exploratory (Phase II)
A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer
This study is looking at a new treatment combination for a type of lung cancer called extensive-stage small cell lung cancer. It combines an approved drug (Nivolumab, also known as OPDIVO) with two standard chemotherapy drugs and a new study drug, BMS-986012, to see if it helps patients.
Romania · Spain · Belgium - recruitingPhase I and Phase II (Integrated)- First administration to humans
Study of IBI3009 alone or in combination with other therapies for extensive-stage small cell lung cancer
This study is looking into a new treatment called IBI3009 for a type of lung cancer that has spread, known as extensive-stage small cell lung cancer. It aims to see if IBI3009 works well on its own or with other medicines, and if it's safe for people.
Poland · Denmark · Spain - recruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
This study compares a new combination medicine, BMS-986489 (BMS-986012 and Nivolumab), with a standard treatment (Atezolizumab), both given with chemotherapy. It's for people with a type of lung cancer called extensive-stage small cell lung cancer who are starting their first treatment.
United States · Argentina · Australia - recruitingPHASE1, PHASE2
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
This study looks at a new drug, ECI830, for advanced breast cancer and other solid tumors. Researchers want to see if it's safe and effective, both alone and with other common cancer medicines.
United States · Australia · Canada - recruitingHuman Pharmacology (Phase I)- Other
A clinical study to test the safety (any good or bad effects) of CC-90011 in combination with standard of care (cisplatin and etoposide), on how long the drug can stay in the body and if it can control the disease of people diagnosed with extensive small cell lung cancer and have not had any previous treatment for the disease. CC-90011, single agent, will be also given in consolidation after completion of the 4 to 6 cycles of chemotherapy
This study looks at a new drug, CC-90011, for extensive small cell lung cancer in people who haven't had treatment before. It checks if the drug is safe, how long it stays in the body, and if it helps control the cancer when given with standard chemotherapy and afterwards on its own.
Spain · Italy - recruitingPHASE3
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
This study is testing a new drug, Pumitamig, with chemotherapy for people with advanced small-cell lung cancer that hasn't been treated before. It aims to see if this new combination works better and is safe compared to a standard treatment.
United States · Australia · China - recruitingNA
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
This study looks at whether regular brain scans alone are as good as scans plus radiation therapy for people with small cell lung cancer. It aims to see if avoiding radiation therapy can improve quality of life and brain health without making outcomes worse.
Austria · Belgium · France - active not recruitingPHASE3
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
This study is looking at a new combination of medicines, tarlatamab and durvalumab, for people with advanced small-cell lung cancer. It wants to see if this combination helps people live longer compared to durvalumab alone, after their initial chemotherapy treatment.
United States · Argentina · Australia - recruitingPHASE3
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
This study looks at a new treatment combination for a type of advanced lung cancer called extensive stage small-cell lung cancer (ES-SCLC). It compares a combination including tarlatamab with a standard treatment to see if it helps people live longer.
United States · Argentina · Australia - active not recruitingPHASE1, PHASE2
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
This study is testing a new combination treatment for a type of lung cancer called Extensive Stage Small Cell Lung Cancer (ES-SCLC). It aims to find a safe dose and see if this new combination works better than current treatments for people newly diagnosed with this aggressive cancer.
United States · Austria · Canada - active not recruitingPHASE2
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
This study is looking at a new treatment called BNT327 for tiny-cell lung cancer. It combines BNT327 with chemotherapy to see how safe and effective it is for people whose cancer is widespread or has come back after other treatments.
United States · Australia · South Korea - active not recruitingPHASE2
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
This study is testing a new drug, Ifinatamab Deruxtecan (I-DXd), for people with extensive-stage small cell lung cancer who have already had other treatments. It aims to find the best dose and see how well it works and if it's safe.
United States · China · France - authorisedPhase I and Phase II (Integrated)- First administration to humans
A Phase I/II open label study of DJI136, a DLL3-targeted CAR-T therapy, in adult patients with ES-SCLC
This study is testing a new type of treatment called DJI136, a CAR-T therapy, for people with advanced small cell lung cancer. It's in early stages to see how safe and effective it is. Researchers are looking at side effects and how well patients respond to the treatment.
Spain · France - authorisedPhase II and Phase III (Integrated)
C6461004 - A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER
This study is testing a new drug, PF-08634404, alongside standard chemotherapy, for people with a type of lung cancer called extensive-stage small cell lung cancer. Researchers want to see if this new combination can help people live longer and improve their health.
France · Italy · Germany